United Immunity, Co., Ltd.

Meet Luc at BioEurope in Stockholm to learn more about United Immunity’s PEG-free myeloid cell targeting P-LNP for the treatment of cancer, fibrosis, inflammation as well as infectious, metabolic, and autoimmune diseases. #innovation #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages #bioeurope

Masato Kishida, President United Immunity with Ying Chen, President of Bayer Japan and Nobu Kazama, Operation Officer of Bayer Japan last week during Bayer Seminar Lunchon at BioJapan / Regenerative Medicine Japan / healthTECH Japan

Takatoshi Soga and Ayaka Matsumoto @ 6th Macrophage Directed Therapies Summit. Takatoshi presented the latest developments of United Immunity’s UI-102 program for the treatment of solid tumors. UI-102 is a TLR7/8 agonist encapsulated by our pullulan nanoparticle that targets DC-SIGN expressing M2-like tumor associated macrophages. #innovation #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages

United Immunity, in collaboration with the University of Tokyo, Kyoto University, Nagasaki University and Aichi Cancer Center, have published data showing that a next-generation COVID-19 vaccine using United’s Myeloid Targeting Platform™ has superior killer T cell induction and infection protection properties in a preclinical animal model. The study was published in the journal npj Vaccines on September 18.   https://lnkd.in/gP6V8HHS   #innovation #covid #nanoparticles #vaccine #LNP #myeloid #macrophages

Meet Masato Kishida during BioJapan in Yokohama. He will be presenting on October 10 at 11:30 during the Luncheon Seminar organized by Bayer. The title of his talk is “Value co-creation through Partnering: Tips for Start-Up Companies”   https://lnkd.in/d6peS7Ax   #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages #innovation #Biojapan

Meet United Immunity and join Luc St-Onge, Head of Business Development at the Alliance for Regenerative Medicine’s 2024 Cell & Gene Meeting on the Mesa.   We are proud to showcase our T-cell booster vaccines that enhance the therapeutic efficacy of CAR-T and TCR T-cells in solid tumors. We achieve this using our proprietary pullulan-based nanoparticles (PNPs) and PEG-free pullulan lipid nanoparticles (P-LNPs) to selectively deliver tumor antigens to dendritic cells and macrophages.   We look forward in collaborating with industry leaders, innovators, and executives to shape the future of #cellandgenetherapy   See you in Phoenix!   #CGMesa24 #CellandGeneTherapy #CellTherapy #GeneTherapy #cancerimmunotherapy

Join Takatoshi at the 6th Annual Macrophage-Directed Therapy Summit on October 1-3 in Boston where he will present the latest development of United Immunity's UI-102 for the treatment of solid tumors resistant to checkpoint inhibitor. UI-102 utilizes our pullulan nanoparticle technology to selectively deliver a TLR7/8 agonist to tumor associated macrophages in order to convert immune resistant cold tumors into immune responsive hot ones.   https://lnkd.in/dpC8RNS   #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages, #MacrophageDirectedTherapiesSummit

Masato Kishida, President of United Immunity, had a productive kick-off meeting with AstraZeneca's alliance management team for the research collaboration on the next-generation lipid nanoparticles for active targeting delivery of mRNA to myeloid cells   #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages

We are honored to announce that Prof. Yvette van Kooyk from Amsterdam University Medical Center is joining United Immunity’s scientific advisory board. Her pioneering work with DC-SIGN will allow us to better understand how our pullulan nanoparticles and pullulan lipid nanoparticles interacts with the receptor to deliver therapeutic payloads selectively to myeloid cells   Press Release: https://lnkd.in/dDFwDZx5 Prof. van Kooyk LinkedIn Profile: https://lnkd.in/dN8FzX3J   #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages

Fascinating discussions and ground-breaking technologies presented today at the 3rd Annual Next Generation Lipid-Based Nanoparticle Delivery Summit in Boston. Takatoshi gave a talk on United Immunity's PEG-Free Myeloid Targeting LNP Platform for the treatment of cancer, infectious diseases, fibrosis, inflammation, autoimmune, and metabolic diseases.   #cancerimmunotherapy #cancertreatment #nanoparticles #vaccine #LNP #myeloid #macrophages